EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Molecular Docking of Novel Miscellaneous Chalcones as p38α Mitogen‐Activated Protein Kinase Inhibitors

Mai M Zeid, Osama M El-Badry, Salwa Elmeligie, Rasha A Hassan

Chemistry & Biodiversity · 2024

DOI: 10.1002/cbdv.202400077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2024. Verfasst von Mai M Zeid und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ahram Canadian University, 6th of October City, Giza, Egypt. Hauptthemen laut MEDLINE: Mitogen-Activated Protein Kinase 14, Chalcones, Antineoplastic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New chalcones were synthesized and evaluated to serve as p38‐α type of mitogen‐activated protein kinase (MAPK) inhibitors. According to the National Cancer Institute, the findings indicated that at a 10 μM dosage, compounds 3a and 6 were the most active among all the compounds examined, with mean growth inhibition% of 94.83 and 58.49, respectively. In 5‐dose testing, they showed anticancer activity in the micro‐molar range with GI 50 in the range of 1.41–46.1 and 2.07–31.3 μM, respectively. Besides, powerful activity, especially against the leukaemia cell lines and good selectivity to cancer cells compared to normal PCS‐800‐017 with a selectivity index=12.41 and 23.77, respectively. Compounds 3a and 6 inhibited p38α MAPK with IC 50 values of 0.1462±0.0063 and 0.4356±0.0189 μM, correspondingly. 3a showed good inhibition for HL‐60(TB) cells and induced cell cycle arrest in HL‐60(TB) cells at the G2/M phase. Besides, it elevated the total apoptosis by 14.68‐fold and increased the caspase‐3 level by 3.52‐fold compared with doxorubicin, which raised it by 4.30‐fold, inducing apoptosis by acting as caspase‐dependent inducers. These results suggest that 3a is a promising antiproliferative and p38α MAPK inhibitor, confirmed by molecular docking with high compatibility 3a with the p38α MAPK binding site.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitogen-Activated Protein Kinase 14ChalconesAntineoplastic AgentsHumansMolecular Docking SimulationCell Cycle CheckpointsDoxorubicinProtein Kinase InhibitorsApoptosisMolecular StructureCell ProliferationStructure-Activity RelationshipCell Line, Tumor

Stichwörter der Autor:innen

Amino chalconesHalogenated chalconesPyrazalone based chalconesSchiff's based chalconesanticancerp38-α MAPK inhibitors

Substanzen

Mitogen-Activated Protein Kinase 14ChalconesDoxorubicinProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ahram Canadian University, 6th of October City, Giza, Egypt.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt, 33 Kasr El-Aini Street, Cairo, Egypt.

Zitieren

APA

Zeid, M. M., El-Badry, O. M., Elmeligie, S., & Hassan, R. A. (2024). Design, Synthesis, and Molecular Docking of Novel Miscellaneous Chalcones as p38α Mitogen‐Activated Protein Kinase Inhibitors. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202400077

Vancouver

Zeid MM, El-Badry OM, Elmeligie S, Hassan RA. Design, Synthesis, and Molecular Docking of Novel Miscellaneous Chalcones as p38α Mitogen‐Activated Protein Kinase Inhibitors. Chemistry & Biodiversity. 2024. doi:10.1002/cbdv.202400077

BibTeX
@article{Zeid2024,
  author = {Zeid, Mai M and El-Badry, Osama M and Elmeligie, Salwa and Hassan, Rasha A},
  title = {Design, Synthesis, and Molecular Docking of Novel Miscellaneous Chalcones as p38α Mitogen‐Activated Protein Kinase Inhibitors},
  journal = {Chemistry & Biodiversity},
  year = {2024},
  doi = {10.1002/cbdv.202400077}
}
Kostenlos starten →